Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
General Internal Medicine
•
Cardiology
•
Cardiovascular Imaging
Should there be age cut-off considerations when ordering TTEs with bubble routinely as part of stroke work-up?
If so, what age group would be less likely to benefit from bubble studies?
Related Questions
What is the role of MRI in assessing the risk of embolism in patients with persistent left ventricular thrombus following myocardial infarction?
What is a reasonable imaging modality for older patients with pAfib already on systemic anticoagulation outpatient but presenting with suspected cardioembolic stroke and TTE without evidence of LV thrombus?
What are some TTE findings that suggest worsening function of a bioprosthetic AVR that would require further surveillance or diagnostic imaging?
How do you distinguish between senile/hypertensive sigmoid septal hypertrophy versus sigmoid septal hypertrophy seen in hypertrophic cardiomyopathy?
Are there other scenarios besides prior history of TIA or stroke or LV dysfunction in which systemic anticoagulation for LV non-compaction would be considered?
What is your approach to checking preoperative cardiac biomarkers such as troponin and BNP?
How do you approach caring for patients admitted with decompensated CHF, but who also exhibit hypotension and do not have overt signs of hypervolemia on exam?
Are there data to support full-dose anticoagulation added to an antiplatelet in recurrent peripheral arterial thrombosis requiring revascularization and stenting?
Where does dronedarone fall in your list of antiarrhythmics drugs to use in terms of efficacy and patient selection in contemporary management of atrial fibrillation?
How do you choose between finerenone and traditional steroidal MRAs for patients with heart failure and mildly reduced or preserved EF, considering recent results showing finerenone's efficacy in reducing heart failure events?